Top Page
Genscript Biotech
(OTC:1548)
Genscript Biotech (1548) vs. iShares MSCI Hong Kong ETF (EWH)
Genscript Biotech Business Overview & Revenue Model
Genscript Biotech Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 594.49M | 839.53M | 625.70M | 490.10M | 390.85M | Gross Profit |
| 272.13M | 409.55M | 304.08M | 282.52M | 255.89M | EBIT |
| 9.28M | -415.79M | -438.11M | -379.29M | -204.55M | EBITDA |
| 70.43M | -249.42M | -389.04M | -341.57M | -174.71M | Net Income Common Stockholders |
| 2.96B | -95.48M | -226.85M | -358.71M | -204.94M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 621.18M | 1.93B | 1.46B | 1.41B | 772.38M | Total Assets |
| 5.28B | 3.39B | 2.55B | 2.23B | 1.45B | Total Debt |
| 723.74M | 416.99M | 349.80M | 156.45M | 55.00M | Net Debt |
| 591.75M | -1.03B | -674.20M | -1.02B | -574.05M | Total Liabilities |
| 954.91M | 1.34B | 1.18B | 846.17M | 631.82M | Stockholders Equity |
| 4.32B | 1.39B | 1.01B | 1.05B | 901.71M |
| Cash Flow | Free Cash Flow | |||
| -72.27M | -444.62M | -336.40M | -269.83M | -272.97M | Operating Cash Flow |
| 75.65M | -286.91M | -120.29M | -136.79M | -151.09M | Investing Cash Flow |
| -1.46B | -357.73M | -443.30M | -212.55M | -100.17M | Financing Cash Flow |
| 66.52M | 1.07B | 419.32M | 902.14M | 624.20M |
Genscript Biotech Technical Analysis
Genscript Biotech Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$24.78B | 27.86 | 31.65% | ― | 4.23% | 47.71% | |
69 Neutral | HK$33.66B | 23.59 | 5.72% | 2.77% | -15.81% | -48.17% | |
64 Neutral | $31.66B | 0.97 | -6.09% | ― | 41.41% | 7.26% | |
54 Neutral | HK$32.35B | ― | -19.78% | ― | 25.96% | 39.58% | |
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
53 Neutral | €32.65B | ― | -32.29% | ― | 43.13% | 28.93% |
Genscript Biotech Corporate Events
Legend Biotech, an associate of GenScript Biotech, announced promising five-year survival data from the CARTITUDE-1 study for its CARVYKTI® therapy in treating multiple myeloma. The data, presented at the 2025 ASCO Annual Meeting, showed that one-third of patients remained progression-free for five years, highlighting the therapy’s potential impact on long-term cancer treatment. Additionally, preliminary results from ongoing studies in solid tumors were also presented, indicating potential advancements in lung and gastric cancer therapies.
Genscript Biotech Corporation held its Annual General Meeting on May 29, 2025, where all proposed resolutions were passed by poll. Key decisions included the re-election of several directors and the reappointment of Ernst & Young as auditors. The meeting also granted the board mandates to issue and repurchase shares, reflecting strategic moves to enhance corporate governance and shareholder value.
The most recent analyst rating on (HK:1548) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
Genscript Biotech Corporation announced the composition and roles of its board of directors, highlighting the establishment of five committees to enhance governance and strategic oversight. This organizational update is likely to strengthen the company’s operational framework and could have implications for its strategic direction and stakeholder engagement.
The most recent analyst rating on (HK:1548) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
Genscript Biotech Corporation has updated the terms of reference for its Nomination Committee, emphasizing the importance of diversity and independent oversight. The committee, which consists of at least three directors with a focus on gender diversity and independent non-executive directors, is tasked with reviewing the board’s structure and skills annually to align with the company’s corporate strategy. This move aims to enhance corporate governance and ensure the board’s composition supports strategic goals, potentially impacting stakeholder confidence positively.
The most recent analyst rating on (HK:1548) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
Legend Biotech, an associate of Genscript Biotech, will present new data on CARVYKTI, a treatment for multiple myeloma, at the 2025 ASCO and EHA annual meetings. This announcement highlights the ongoing development efforts in the CARTITUDE Clinical Development Program, which could have significant implications for the treatment of multiple myeloma and potentially enhance Legend Biotech’s position in the biotech industry.
The most recent analyst rating on (HK:1548) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
GenScript Biotech Corporation, a company incorporated in the Cayman Islands, has announced the financial results of its associate, Legend Biotech Corporation, for the first quarter ended March 31, 2025. Legend Biotech, listed on the Nasdaq Global Selected Market, has filed its Form 6-K with the SEC, detailing its financial performance and recent business highlights. GenScript advises shareholders and potential investors to exercise caution when dealing with its securities, as the financial results pertain solely to Legend Biotech.
The most recent analyst rating on (HK:1548) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
Genscript Biotech Corporation has completed a significant transaction involving the transfer of 300,000,000 Series A Preferred Shares of its subsidiary, Probio Cayman. This transaction, which took place on May 7, 2025, strengthens Genscript’s control over Probio Cayman, increasing its equity interest to approximately 85.09%. This strategic move is likely to enhance Genscript’s market positioning and operational capabilities in the biotech sector.
Genscript Biotech Corporation announced a significant transaction involving the transfer of 300,000,000 Series A Preferred Shares of its subsidiary, Probio Cayman, for approximately US$225.1 million. This transaction will increase Genscript’s equity interest in Probio Cayman from 71.72% to 85.09%, enhancing its control over the subsidiary. The deal, approved by the Board, is considered a connected transaction but is exempt from certain regulatory requirements, reflecting its strategic importance for Genscript’s market positioning and operational control.
Legend Biotech, an associate of Genscript Biotech, announced that CARVYKTI® generated approximately US$369 million in net trade sales for the quarter ended March 31, 2025. This announcement highlights the product’s strong market performance and its potential impact on the company’s financial health and industry standing.
Genscript Biotech Corporation has announced its 2025 Annual General Meeting, scheduled for May 29, 2025, in Nanjing, China. The meeting will address several key resolutions, including the adoption of the company’s audited financial statements, re-election of board members, and re-appointment of auditors. Additionally, the company seeks approval to allow its directors to issue new shares, a move that could potentially impact its capital structure and shareholder value.
Genscript Biotech Corporation announced a supplemental release regarding the financial results of its listed associate, Legend Biotech Corporation, for the fourth quarter and the year ended December 31, 2024. The announcement includes a Chinese translation of Legend Biotech’s press release, originally published in English, detailing financial performance and recent business highlights. Stakeholders are advised to consider investment risks carefully.
Genscript Biotech reported a significant increase in profit for the year ended December 31, 2024, primarily due to a gain from the deconsolidation of its cell therapy business, amounting to approximately US$3.2 billion. Despite a stable gross profit and a modest revenue growth of 6.1%, the adjusted net profit from continuing operations saw a slight increase of 2.9%, reflecting the company’s strategic adjustments and financial resilience.
Genscript Biotech Corporation announced the financial results of its associate, Legend Biotech Corporation, for the fourth quarter and year ended December 31, 2024. Legend Biotech, in which Genscript holds a 47.51% stake, filed its financial results with the SEC, highlighting recent business achievements. Shareholders are advised to consider investment risks when dealing with Genscript’s securities.
Genscript Biotech Corporation has announced the redesignation of Dr. Ross Allen Grossman from a non-executive Director to an independent non-executive Director, effective March 11, 2025. This change in the board’s composition reflects the company’s strategic focus on strengthening its governance structure, potentially enhancing its industry positioning and stakeholder confidence.
Genscript Biotech Corporation has announced the composition of its board of directors and the roles they will undertake. The board includes a mix of executive, non-executive, and independent non-executive directors, with various members serving on five established committees. This announcement highlights the company’s commitment to strong governance and strategic oversight, which is crucial for maintaining its competitive position in the biotechnology sector.